Table 3.
Univariate and multivariate Cox regression analysis for prediction of OS after RC for NSCLC.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Hazard ratio (95%CI) | P-value | Hazard ratio (95%CI) | P-value | |
| Gender, n (%) | 0.004 | 0.930 | ||
| Male | Ref | Ref | ||
| Female | 0.812 (0.705-0.936) | 0.985 (0.697-1.391) | ||
| Age(years) | 0.001 | 0.002 | ||
| <60 | Ref | Ref | ||
| ≥60 | 0.753 (0.647-0.876) | 1.659 (1.211-2.272) | ||
| Smoking, n (%) | <0.001 | 0.015 | ||
| Yes | Ref | Ref | ||
| No | 0.775 (0.674-0.890) | 1.528 (1.087-2.148) | ||
| Tumor size, cm | <0.001 | 0.301 | ||
| ≤5 | Ref | Ref | ||
| >5 | 0.597 (0.499-0.714) | 1.254 (0.817-1.926) | ||
| TNM, n (%) | <0.001 | 0.003 | ||
| LG | Ref | |||
| HG | 0.283 (0.210-0.382) | Ref | ||
| Microvascular invasion | <0.001 | 0.557 (0.379-0.817) | 0.002 | |
| Yes | Ref | Ref | ||
| No | 0.577 (0.500-0.667) | 1.675 (1.205-2.326) | ||
| Ki67 (%) | <0.001 | <0.001 | ||
| <15 | Ref | Ref | ||
| ≥15 | 0.552 (0.473-0.644) | 1.940 (1.383-2.721) | ||
| Adjuvant Therapy*, n | <0.001 | 0.224 | ||
| (%) | ||||
| Yes | Ref | Ref | ||
| No | 1.303 (1.133-1.499) | 0.824 (0.603-1.126) | ||
| WBC (x109/L) | 0.300 | |||
| <5.775 | Ref | |||
| ≥5.775 | 0.915 (0.774-1.082) | |||
| PLT (x109/L) | <0.001 | <0.001 | ||
| <234.5 | Ref | Ref | ||
| ≥234.5 | 0.764 (0.662-0.882) | 1.875 (1,330-2.592) | ||
| PLT2 | <0.001 | 0.655 | ||
| <253.5 | Ref | Ref | ||
| ≥253.5 | 0.664 (0.575-0.766) | 0.918 (0.631-1.335) | ||
| PPR | <0.001 | <0.001 | ||
| <1.21 | Ref | Ref | ||
| ≥1.21 | 0.672 (0.584-0.772) | 2.046 (1.428-2.932) | ||
Abbreviation: CI, confidence interval; HG, high grade; NSCLC, non-small cell lung cancer; TNM, Tumor Node Metastasis; WBC, white blood cell; PLT, preoperative platelet; PLT2, postoperative platelet; PPR, postoperative platelet/preoperative platelet ratio; Ref, reference. * Adjuvant radiotherapy and/or adjuvant chemotherapy.